DOCSLIB.ORG

Aldrichimica Acta 34, 2001

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aldrichimica Acta 34, 2001 1951–2001: FIFTY YEARS OF CHEMISTS HELPING CHEMISTS AldrichimicaAldrichimica AACTACTA VOL.34, NO.1 • 2001 Preparation of Optically Active α-Amino Acids Alkoxymethylenemalonates in Organic Synthesis CHEMISTS HELPING CHEMISTS 53,182-0 N,N’-Di-(tert-butoxycarbonyl)thiourea, 97% 54,548-1 (1R,2S)-1-Phenyl-2-(1-pyrrolidinyl)-1-propanol, 98% 54,897-9 (1S,2R)-1-Phenyl-2-(1-pyrrolidinyl)-1-propanol, 98% O S O This diprotected thiourea is widely used in the synthesis of heterocycles, including a ONN O H H pentacyclic guanidine system as an These norephedrine derivatives are intermediate to ptilomycalin A,1 and, recently, HO N HO N useful chiral mediators and have in the preparation of p-N,N’-bis-Boc-guanidophenol, a key intermediate for the applications in the enantioselective preparation of a series of aryl o-aroylbenzoates as serine protease inhibitors.2 CH3 CH3 addition of acetylides to carbonyl (1) Nagasawa, K. et al. Tetrahedron 2000, 56, 187. (2) Jones, P.B.; Porter, N.A. J. Am. Chem. Soc. compounds. Examples include the 54,548-1 54,897-9 1999, 121, 2753. synthesis of the HIV-1 reverse transcriptase inhibitor DMP 2661 and the enantioselective addition of diethylzinc to aldehydes.2 54,036-6 1,1-Diethoxy-3-methyl-2-butene, 97% (1) Pierce, M.E. et al. J. Org. Chem. 1998, 63, 8536. (2) Soai, K. et al. ibid. 1991, 56, 4264. OEt This acetal has been utilized in the synthesis of the related 1-alkoxy-3-phenylselenoalkenes and 3-phenylselenoalkanals,1 OEt and in the preparation of 2,2-dimethylchromenes from 54,174-5 Tri-O-acetyl-β-D-arabinosylbromide, 95% electron-deficient phenols.2 (1) Nishiyama, Y. et al. Tetrahedron Lett. 1998, 39, 8685 (2) North, J.T. et al. J. Org. Chem. 1995, 60, 3397. OBrAmong the many applications for this protected bromosugar, the solid-state reaction to make glyco- pyranosyl pyrimidine nucleosides,1 the novel synthesis of 16,345-7 Dimethyl L-tartrate, 99% (99+% ee/GLC) AcO OAc 2 OAc thioglycosides, and the high-yield preparation of pyranoid glycals3 are some of the ones that have been cited. O H OH O Recent citations for this versatile chiral building (1) Im, J. et al. Tetrahedron Lett. 1997, 38, 451. (2) Pakulski, Z. et al. Tetrahedron 1994, 50, 2975. CH3OCCCCOCH3 block include the enantioselective synthesis (3) Kovács, G. et al. ibid. 1999, 55, 5253. HO H of α-bromo carbonyl and carboxylic acid derivatives,1 and the synthesis of enantiomerically pure spirane porphyrazines.2 (1) Boyes, S.A.; Hewson, A.T. J. Chem. Soc., Perkin Trans.1 2000, 2759. (2) Hachiya, S.-i. et al. 52,869-2 2-(6-Bromohexyloxy)tetrahydro-2H-pyran, 97% Tetrahedron 2000, 56, 6565. This THP-protected bromoalcohol is an important building block used in the synthesis 46,944-0 (R)-(+)-1-(tert-Butoxycarbonyl)-2-pyrrolidinemethanol, 97% Br OO of alkaloids,1 symmetrical olefins,2 and 14-membered macrocyclic ethers.3 This protected pyrrolidinemethanol was used in a recent OH (1) Kaiser, A. et al. J. Org. Chem. 1999, 64, 3778. (2) Poulain, S. et al. Tetrahedron Lett. 1996, 37, N study of 3-substituted indoles as potential antimigraine 7703. (3) Clyne, D.S.; Weiler, L. Tetrahedron 1999, 55, 13659. drugs.1 It was also utilized in the preparation of a novel, OO potent, and selective 5-HT7 antagonist via elongation of the side chain followed by transformation into the protected 51,587-6 Imidazole, trifluoromethanesulfonate salt, 97% piperidinylethylpyrrolidine, subsequent deprotection and arylsulfonylation.2 (1) Sternfeld, F. et al. J. Med. Chem. 1999, 42, 677. (2) Lovell, P.J. et al. ibid. 2000, 43, 342. + NH O This triflate has been used as a coupling agent for -O SCF oligonucleotide synthesis1 and as a reagent for the N 3 synthesis of aryl triflates.2 53,673-3 2-Fluoro-6-methoxybenzaldehyde, 98% H O (1) Hayakawa, Y.; Kataoka, M. J. Am. Chem. Soc. 1998, 120, 12395. (2) Effenberger, F.; Mack, K.E. Tetrahedron Lett. 1970, 3947. CHO On conversion to a dinitro ester, the aryl fluorine acts as a CH3O F useful leaving group early in the synthesis of the macrolactam portion of the ansamycin antibiotic 54,039-0 (3,4-Dihydro-1-naphthyloxy)trimethylsilane, 97% (+)-thiazinotrienomycin E. Smith, A.B., III; Wan, Z. J. Org. Chem. 2000, 65, 3738. OSiMe3 The titanium tetrachloride promoted reaction of this trimethylsilyl enol ether with ethylene oxide affords the homoaldol-type 1 product in moderate yield. In other studies, C2-symmetric 54,331-4 2-Fluoro-5-iodobenzaldehyde, 97% copper complexes have been shown to catalyze the CHO The related iodobenzo[b]thiophenecarboxylate ester has been enantioselective amination of,2 or ketomalonate addition to,3 this enol silane. F synthesized in moderate yield from this dihalo aldehyde. (1) Lalic, G. et al. Tetrahedron Lett. 2000, 41, 763. (2) Evans, D.A.; Johnson, D.S. Org. Lett. 1999, 1, Bridges, A.J. et al. Tetrahedron Lett. 1992, 33, 7499. 595. (3) Reichel, F. et al. J. Chem. Soc., Chem. Commun. 1999, 1505 I Aldrichimica ACTA VOL. 34, NO. 1 • 2001 “Please Aldrich Chemical Co., Inc. To request your FREE subscription to the 1001 West Saint Paul Ave. Bother Aldrichimica Acta, Milwaukee, WI 53233 USA please call: 800-558-9160 (USA), To Place Orders write: Attn: Mailroom Us.” Telephone 800-558-9160 (USA) Aldrich Chemical Co., Inc. or 414-273-3850 P.O. Box 355 FAX 800-962-9591 (USA) Milwaukee, WI 53201-9358 or 414-273-4979 or email: [email protected] Mail P.O. Box 2060 Clint Lane, President Milwaukee, WI 53201 USA International customers, please contact your local Sigma-Aldrich office. General Correspondence The Aldrichimica Acta is also available on the OO Internet at http://www.sigma-aldrich.com. Editor: Sharbil J. Firsan, Ph.D. S CH3 P.O. Box 355, Milwaukee, WI 53201 USA N OCH3 Customer & Technical Services Customer Inquiries 800-558-9160 Aldrich brand products are sold through Sigma-Aldrich, Inc. Professor Ahcène Boumendjel of the Technical Service 800-231-8327 Sigma-Aldrich, Inc. warrants that its products conform to the Université Joseph Fourier (La Tronche, Sigma-Aldrich Fine Chemicals 800-336-9719 information contained in this and other Sigma-Aldrich France) kindly suggested that we make Custom Synthesis 800-336-9719 publications. Purchaser must determine the suitability of the product for its particular use. See reverse side of invoice or N-methoxy-N-methyl-2-(phenylsulfinyl)- Flavors & Fragrances 800-227-4563 1 packing slip for additional terms and conditions of sale. acetamide. This amide is useful for International 414-273-3850 the homologation of alkyl halides to 24-Hour Emergency 414-273-3850 α,β-unsaturated N-methoxy-N-methyl- Web Site http://www.sigma-aldrich.com For worldwide contact information, please see the E-Mail [email protected] inside back cover. amides, which are valuable intermediates in the synthesis of natural products and Aldrichimica Acta is a publication of Aldrich. Aldrich is a member of the Sigma-Aldrich family. © 2001 by Sigma-Aldrich Co. therapeutics.2 Printed in the United States. (1) Beney, C.; Boumendjel, A.; Mariotte, A.-M. Tetrahedron Lett. 1998, 39, 5779. (2) Sibi, M. About Our Cover P. Org. Prep. Proced. Int. 1993, 25, 15. dgar Degas’s Ballet Scene (pastel on 51,139-0 Ecardboard, 30I in. x 43J in.) was N-Methoxy-N-methyl-2-(phenyl- executed ca. 1907 when the artist was in his sulfinyl)acetamide, 96% seventies, and not long before his career was cut short by his growing blindness. The subject of the picture is one indelibly identified Naturally, we made this useful reagent. with Degas who, unlike his impressionist It was no bother at all, just a pleasure to friends, more often chose to represent urban be able to help. scenes than the country landscapes they preferred. Life in the cafés, at the racetrack, Do you have a compound that you wish Aldrich in the theatre, at the opera, and in particular could list, and that would help you in your at the ballet, was what most attracted him. research by saving you time and money? If so, However, it was not the glamour, the drama, and the sumptuous spectacle of a ballet please send us your suggestion; we will be delighted to give it careful consideration. You performance that interested him, but the behind-the-scenes work that goes on before can contact us in any one of the ways shown the dancers go on stage. His goal was to distill from the constantly changing on this page or on the inside back cover. movements and postures of the dancers a single moment which would capture the essence of motion, and it was the exercises, the rehearsals, the minutes before a performance that gave him the opportunity to do this. This goes some way towards explaining the medium he used for this work, which is Table of Contents not an oil painting on canvas but a picture executed in pastel chalks, a dry medium similar to the charcoal he often used to sketch quickly the varied life of the city of Paris The Preparation of Optically Active all around him. Through his depiction of varied postures and gestures, Degas leads α-Amino Acids from the Benzophenone the eye along a curving line from the lower right corner of the picture to the left, Imines of Glycine Derivatives.................3 contrasting the more static attitudes of the three figures in the right foreground with the –M. J. O’Donnell animated movements of the dancers further back on the left, to capture in an essentially Alkoxymethylenemalonates motionless work of art a sense of the dynamic actions of a group of dancers at work.
Load more

Recommended publications
  • Certificate ISO 14001 From
    CERTIFICATE This is to certify that Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany with the organizational units/sites as listed in the annex has implemented and maintains an Environmental Management System. Scope: Development, production and distribution of pharmaceuticals, chemical products and analytical systems. Through an audit, documented in a report, it was verified that the management system fulfills the requirements of the following standard: ISO 14001 : 2015 Certificate registration no. 005356 UM15 Valid from 2020-12-17 Valid until 2023-12-16 Date of certification 2020-11-18 DQS GmbH Markus Bleher Managing Director Accredited Body: DQS GmbH, August-Schanz-Straße 21, 60433 Frankfurt am Main, Germany 1 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 005356 Development, production and distribution of Merck KGaA pharmaceuticals, chemical products and Frankfurter Straße 250 analytical systems. 64293 Darmstadt Including: Real Estate GmbH Merck Performance Materials Germany GmbH Merck Healthcare KGaA With regional offices at: Roesslerstrasse 96 64293 Darmstadt Waldstrasse 3 64331 Weiterstadt 450237 Merck S.A. Production and distribution of pharmaceuticals Estrada dos Bandeirantes, 1099 and chemical products. Rio de Janeiro - RJ 22710-571 Brazil 450240 Merck Serono SA Production and distribution of Zone Industrielle de l´Ouriettaz pharmaceuticals. 1170 Aubonne Switzerland 450325 Merck Serono SA Development and production of Corsier-sur-Vevey pharmaceuticals. Rte de Fenil 25 1804 Fenil-sur-Vevey Switzerland This annex (edition: 2020-11-18) is only valid in connection with the above-mentioned certificate. 2 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 450241 Merck & Cie Production of chemical products.
    [Show full text]
  • Geschäftsbericht 2017
    350 Geschäftsbericht 2017 1668 Auszug aus dem „Apotheken-Privileg“ des Landesherren für den Unternehmensgründer FRIEDRICH JACOB MERCK: „ [Er soll die Apotheke] der ordnung gemeess mit guten frischen, zu ein= und anderen Curen dienlichen heil- samen Medicamentis und wahren also genugsamlich versehen, und damit fort und fort würklich continuiren, daß kein Mangel erscheine.“ 2018 STEFAN OSCHMANN Vorsitzender der Geschäftsleitung und CEO von Merck „ Wissenschaftliche Neu- gierde treibt uns seit 350 Jahren an. Durch sie wurden wir Techno logie- Pioniere. Und jetzt gestalten wir die digi tale Revolution mit.“ DIE ZUKUNFT SPRICHT SIMON CLARK sechs Jungforscherinnen und -forscher promoviert im Bereich Atmosphä- rische Physik an der University of Exeter. Auch in seinen YouTube- Videos geht es vor allem um physi- kalische Themen. „ Die Dinge verbessern sich nur, wenn es Leute gibt, die ver- rückte Ideen haben und etwas Neues ausprobieren.“ Treibt Merck frische Ideen voran? Die Antwort finden Sie auf Seite 10. SAMUEL CUNHA ist ein brasilianischer Parasitologe, der seine Leidenschaft für Biologie mit vielen Fans auf YouTube teilt. „ Um leidenschaftlich zu bleiben, muss man immer an die Zukunft denken, an das mögliche Ergebnis seiner Arbeit.“ Wie hält es Merck mit diesem Grundsatz? Die Antwort lesen Sie auf Seite 11. EVA AMSEN ist promovierte Biochemikerin, Autorin und Wissenschaftsvermittlerin in London. „ Für Wissen- schaftler ist es wichtig, dass sie sich nicht nur mit ihren Kollegen austauschen, sondern auch mit Menschen aus völlig anderen Bereichen – zum Bei- spiel mit Künstlern.“ Wird interdisziplinärer Austausch bei Merck gelebt? Die Antwort lesen Sie auf Seite 13. INÉS DAWSON ist promovierte Biologin in Oxford und beliebte YouTuberin. „ Forschung und Kreativität sollten Hand in Hand gehen, da nicht alle Probleme eine eindeutige Lösung haben.“ Fördert Merck Kreativität? Die Antwort finden Sie auf Seite 14.
    [Show full text]
  • Aldrichimica Acta Volume 42 No. 1
    DEDICATED TO DR. ALFRED BADER ON THE OCCASION OF HIS 85TH BIRTHDAY VOL. 42, NO. 1 • 2009 The Super Silyl Group in Diastereoselective Aldol and Cascade Reactions Iterative Cross-Coupling with MIDA Boronates: towards a General Strategy for Small-Molecule Synthesis Editorial “Please Call Me Alfred” On April 28 of this year, Dr. Alfred Bader, undeniably the world’s Centre of Queen’s University best-known Chemist Collector, celebrated his 85th birthday. Alfred’s in Kingston, Ontario (Canada). amazing life story has been covered extensively in books, magazines, This gift is one of several and lectures, by Alfred himself and by others, and need not be sizeable ones that he has repeated here. Furthermore, most of our readers are undoubtedly made to Queen’s in gratitude aware of Alfred’s strong connections, past and present, not only for the education he received to Sigma-Aldrich, but also to the Aldrichimica Acta, which he has there in the 1940s. showered with his attention for many years. Many of Alfred’s Lesser known, but not paintings have graced the covers of the Acta, including this issue, less important to Alfred, is his which is featuring one of Alfred’s favorite paintings. Bible scholarship, particularly We honor and thank Alfred for his outstanding contributions of Old Testament themes, to Sigma-Aldrich and to the worlds of chemistry, business, and art. which he has studied all his To what he calls the “ABC” (Art, Bible, Chemistry) of his life, one life and taught for a good Photo Courtesy of Alfred Bader should add a “D” for Donating.
    [Show full text]
  • Acta Archive Indexes Directory
    VOLUME 50, NO. 1 | 2017 ALDRICHIMICA ACTA Acta Archive Indexes • Chronological • Affiliations 4-Substituted Prolines: Useful Reagents in Enantioselective HIMICA IC R A Synthesis and Conformational Restraints in the Design of D C L T Bioactive Peptidomimetics A A • Authors • Painting Clues Recent Advances in Alkene Metathesis for Natural Product Synthesis—Striking Achievements Resulting from Increased 1 7 9 1 Sophistication in Catalyst Design and Synthesis Strategy 68 20 • Titles The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Chronological YEAR Vol. No. Authors Title Affiliation 1968 1 1 Buth, William F. Fragment Information Retrieval of Structures Aldrich Chemical Co., Inc. 1 Bader, Alfred Chemistry and Art Aldrich Chemical Co., Inc. 1 Higbee, W. Edward A Portrait of Aldrich Chemical Company Aldrich Chemical Co., Inc. 2 West, Robert Squaric Acid and the Aromatic Oxocarbons University of Wisconsin at Madison 2 Bader, Alfred Of Things to Come Aldrich Chemical Co., Inc. 3 Koppel, Henry The Compleat Chemists Aldrich Chemical Co., Inc. 3 Biel, John H. Biogenic Amines and the Emotional State Aldrich Chemical Co., Inc. 4 Biel, John H. Chemistry of the Quinuclidines Aldrich Chemical Co., Inc. Warawa, E.J. 4 Clark, Anthony M. Dutch Art and the Aldrich Collection Aldrich Chemical Co., Inc. 1969 2 1 May, Everette L. The Evolution of Totally Synthetic, Strong Analgesics National Institutes of Health 1 Anonymous Computer Aids Search for R&D Chemicals Reprinted from C&EN 1968, 46 (Sept. 2), 26-27 2 Hopps, Harvey B. The Wittig Reaction Aldrich Chemical Co., Inc. Biel, John H.
    [Show full text]
  • MERCK Kgaa DARMSTADT, GERMANY
    MERCK KGaA DARMSTADT, GERMANY Annual Financial Statements 2016 DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSig- ma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. For nearly 350 years, curious people at our company have been bringing ideas to life. As a global science and technology company, a passion for research and discovery is our most valuable resource. With our three business sectors, namely Healthcare, Life Science and Performance Materials, we improve the quality of life of patients, in- crease the success of our customers, and offer solutions for diverse challenges. Curiosity is and remains our strongest driving force for future-oriented innovations. Annual Financial Statements 3 Combined Management Annual Financial Statements Report 112 – 158 03 – 110 112 Balance Sheet as of December 31, 2016 113 Income Statement from the period 003 Fundamental Information about the Group from January 1 to December 31, 2016 003 The Group 114 Notes to the Annual Financial Statements 010 Objectives and strategies 115 Notes to the Balance Sheet 016 Internal Management System 125 Notes to the Income Statement 020 Corporate Responsibility 129 Other Disclosures 028 Research and development 132 Members of the Executive Board of Merck KGaA, 040 People Darmstadt, Germany 133 Supervisory Board 046 Report on Economic Position 134 Disclosures in accordance with section 160 (1) no.
    [Show full text]
  • Professor Dervan's Curriculum Vitae
    Curriculum Vitae Name: Peter B. Dervan Address: Division of Chemistry and Chemical Engineering California Institute of Technology, Pasadena, CA 91125 tel: 626-395-6002; fax: 626-683-8753; e-mail: [email protected] Education 1967 B.S., Chemistry; Boston College 1972 Ph.D., Chemistry; Yale University Academic Career 1973 NIH Postdoctoral Fellow, Stanford University 1973 Assistant Professor of Chemistry, California Institute of Technology 1979 Associate Professor of Chemistry, California Institute of Technology 1982- Professor of Chemistry, California Institute of Technology 1988- Bren Professor, California Institute of Technology 1994-99 Chair, Division of Chemistry and Chemical Engineering 2020 Bren Professor of Chemistry, Emeritus Awards 1972 Wolfgang Prize for Distinguished Graduate Studies, Yale University 1977 Alfred P. Sloan Research Fellow 1978 Camille and Henry Dreyfus Teacher-Scholar 1983 John Simon Guggenheim Memorial Fellow 1985 ACS Nobel Laureate Signature Award for Graduate Education in Chemistry 1986 Arthur C. Cope Scholar Award, American Chemical Society 1986 Elected member, National Academy of Sciences 1988 Elected member, American Academy of Arts and Sciences 1988 Harrison Howe Award, American Chemical Society, Rochester Section 1993 Arthur C. Cope Award, American Chemical Society 1993 Willard Gibbs Medal, American Chemical Society, Chicago Section 1994 Nichols Medal, American Chemical Society, New York Section 1996 Maison de la Chimie Foundation Prize, France 1997 Elected member, National Academy of Medicine 1998 Remsen Award, American Chemical Society, Baltimore Section 1998 Kirkwood Medal, American Chemical Society, New Haven Section 1999 Alfred Bader Award, American Chemical Society 1999 Max Tishler Prize, Harvard University 1999 Linus Pauling Medal, American Chemical Society, Oregon Portland Puget Sound Section 1999 Richard C.
    [Show full text]
  • Annual Financial Statements TABLE of CONTENTS Annual Financial Statements
    Annual Financial Statements TABLE OF CONTENTS Annual Financial Statements Combined Annual Financial Management Report Statements 4 Fundamental Information 140 Balance Sheet as of December 31, 2020 about the Group 141 Income Statement for the period 4 The Group from January 1 to December 31, 2020 16 Strategy 142 Statement of Changes in Fixed Assets 25 Internal Management System 143 Notes for the fiscal year 2020 31 Sustainability 147 Notes to the Balance Sheet 40 Research and Development 157 Notes to the Income Statement 57 People 161 Other Disclosures 165 Members of the Executive Board 67 Report on Economic Position of Merck KGaA, Darmstadt, Germany 67 Macroeconomic and 166 Members of the Supervisory Board Sector-Specific Environment of Merck KGaA, Darmstadt, Germany 71 Review of Forecast 168 Disclosures in accordance with against Actual Business Developments section 160 (1) no. 8 of the German 79 Course of Business and Economic Position Stock Corporation Act (AktG) 79 Group 170 List of Shareholdings of Merck KGaA, Darmstadt, Germany, as of December 31, 2020 89 Healthcare 194 Reproduction of the Independent Auditor’s 95 Life Science Report 99 Performance Materials 201 Responsibility Statement in accordance 103 Corporate and Other with section 264 (2) sentence 3 HGB and section 289 (1) sentence 5 HGB 104 Report on Risks and Opportunities 202 Report of the Supervisory Board 121 Report on Expected Developments 206 Financial Calendar 126 Report in accordance with Section 315a (1) of the German Commercial Code (HGB) 129 Additional Information
    [Show full text]
  • Annual Report 2017
    350 Annual Report 2017 1668 Excerpt from the “Pharmacy Privilege” issued by the ruling court to the company founder FRIEDRICH JACOB MERCK: “ [He shall run the pharmacy] ensuring that it is properly stocked with good, freshly prepared medicinal products at all times so as to cure ailments and prevent ill health.” 2018 STEFAN OSCHMANN Chairman of the Executive Board and CEO of Merck “ Scientific curiosity has been a major driver of our success for 350 years. It has enabled us to pioneer new technologies. And now we are helping to shape the digital revolution.” THOUGHTS ON THE FUTURE SIMON CLARK Six young researchers is a PhD student in climate physics at the University of Exeter. His YouTube videos also mainly address topics in physics. “ Things only improve if there are people who have crazy ideas and try out something new.” Does Merck drive fresh ideas? Find the answer on page 10. SAMUEL CUNHA is a Brazilian parasitologist who shares his passion for biology with numerous followers on YouTube. “ To stay passionate, we always have to think of the future,of the poten- tial result of our work.” What does Merck think of this principle? Find the answer on page 11. EVA AMSEN is a biochemist, writer and science communicator based in London. “ For scientists it is important to exchange ideas not only with their colleagues, but also with people from totally different fields – for example, with artists.” Does Merck practice interdisciplinary exchange? Find the answer on page 13. INÉS DAWSON is a biologist, a PhD student at Oxford and a popular YouTube blogger.
    [Show full text]
  • Externer/Interner Brief, Telefax Für Word 2000, Merck Darmstadt
    Progress Report Implementation of the ten principles of the UN Global Compact Period: May 2011 to December 2012 CEO’s Declaration of continued support We at Merck take our corporate responsibility seriously − it is an integral part of our entrepreneurial approach. Responsible conduct founded on clearly defined values is a key factor in Merck nearing its 350th anniversary. We would like to continue along this path. We are therefore reaffirming our commitment to the United Nations Global Compact, which we joined in 2005. We continue to support the ten principles established by the compact, which cover human rights, labor regulations, environmental protection, and anti-corruption. One example of how we actively promote human rights is our commitment to access to health, which means facilitating access to medicines for people in developing countries. After all, according to Article 25 of the UN’s Universal Declaration of Human Rights, medical care is a universal human right. Being a pharmaceutical, chemical and life science company, we can contribute our expertise in a particularly meaningful manner here. For example, we are collaborating with the World Health Organization (WHO) to combat the tropical disease schistosomiasis in Africa, where we aim to help eliminate the disease by donating praziquantel tablets. In 2012, we decided to expand our commitment and increase the tablet donation tenfold, from 25 million per year to 250 million per year in the medium term. Our Praziquantel Donation Program is, however, only one of many examples of how we are implementing the principals of the Global Compact at Merck despite economically challenging times.
    [Show full text]
  • Merck Serono Constantly Seeks: • Novel Therapeutic Agents and Drug Targets in Our Key Therapeutic Areas
    PharmaForum 2010, am 2. November in Mainz 1. Company Merck is the world’s oldest pharmaceutical and chemical company with approximately 40.000 employers in 64 countries. Its roots date back to 1668, when Friedrich Jacob Merck purchased the "Angel Pharmacy" in Darmstadt – still owned by the Merck family today. Around 30% of the company’s total capital is publicly traded, while the Merck family owns an interest of about 70% via the general partner E. Merck KG. Merck shares have been included in the DAX ® 30 since 2007. In early 2007, the acquisition of the Swiss firm Serono, Europe’s leading biopharmaceutical company, was completed. The scope of this strategically compelling combination is expected to raise Merck’s competitiveness in the global pharmaceutical market. Analogical, Merck strengthened its chemical sector with the acquisition of Millipore in 2010. 2. Core Competences 2.1 Pharmaceuticals Merck discovers, develops, manufactures and markets innovative prescription drugs as well as over-the-counter products. Merck develop therapies for high unmet medical needs. Through their targeted effect, these help patients to live a longer and better life. Our over-the-counter products can prevent disease and relieve minor complaints. Key therapeutic areas and products ⇒ Oncology: Erbitux® (metastatic colorectal cancer, head and neck cancer), UFT® (colorectal cancer) ⇒ Neurodegenerative Diseases: Rebif® (multiple sclerosis) ⇒ Fertility: Gonal-f®, Ovitrelle®, Pergoveris™, Luveris®, Crinone®, Cetrotide® ⇒ Endocrinology: Saizen® (growth hormone disorders), Serostim® (HIV- associated wasting), Kuvan® (phenylketonuria) ⇒ CardioMetabolic Care: Glucophage® family (type 2 diabetes), Concor® family (cardiovascular diseases), Euthyrox® (thyroid diseases) ⇒ Other therapeutic areas: Cyanokit® (cyanide poisoning) and other products Seite 2 2.2 Chemicals With a range of more than 40.000 products, Merck Millipore ranks third in the life science market.
    [Show full text]
  • Annual Report 2014 Delivering Growth
    ANNUAL REPORT 2014 DELIVERING GROWTH MERCK GROUP → KEY FIGURES Change € million 2014 2013 in % Total revenues 11,500.8 11,095.1 3.7 Sales 11,291.5 10,700.1 5.5 Operating result (EBIT) 1,762.0 1,610.8 9.4 Margin (% of sales) 15.6 15.1 EBITDA 3,122.9 3,069.2 1.7 Margin (% of sales) 27.7 28.7 EBITDA pre one-time items 3,387.7 3,253.3 4.1 Margin (% of sales) 30.0 30.4 Earnings per share (€)1 2.66 2.77 –4.0 Earnings per share pre one-time items (€)1 4.60 4.39 4.8 Business free cash flow 2,605.1 2,960.0 –12.0 1 Taking into account the share split; previous year’s figures have been adjusted accordingly. See “Earnings per share” in the Notes to the Consolidated Financial Statements. MERCK GROUP → SALES € million 2014 → 11,291.5 2013 → 10,700.1 2012 → 10,740.8 2011 → 9,905.9 2010 → 8,928.9 MERCK GROUP → EBITDA PRE ONE-TIME ITEMS € million 2014 → 3,387.7 2013 → 3,253.3 2012 → 2,964.9 2011 → 2,723.8 2010 → 2,545.0 MERCK GROUP → Merck is a leading company for innovative and top-quality high- tech products in healthcare, life science and performance materials. Around 39,000 Merck employees work in 66 countries MERCK GROUP MERCK structure Company to improve the quality of life for patients, to foster the success → of customers and to help meet global challenges. MERCK GROUP → BUSINESS SECTORS AND BUSINESSES as of January 1, 2015 Merck Group Performance Healthcare Life Science Business sectors Materials Performance Merck Serono Merck Millipore Materials Businesses Consumer Health Allergopharma Biosimilars Effective January 1, 2015 Merck changed the structure of its financial reporting.
    [Show full text]
  • Curriculum Vitae - Victor Algirdas Snieckus
    HETEROCYCLES, Vol. 88, No. 1, 2014 5 HETEROCYCLES, Vol. 88, No. 1, 2014, pp. 5 - 43. © 2014 The Japan Institute of Heterocyclic Chemistry DOI: 10.3987/COM-13-S(S)CV CURRICULUM VITAE - VICTOR ALGIRDAS SNIECKUS Queen's University Department of Chemistry Tel: (613) 533-2239 Kingston, Ontario K7L 3N6 Fax: (613) 533-6089 E-mail: [email protected] PERSONAL DATA Born Kaunas, Lithuania, 1 August, 1937 Citizenship Canadian Married Anne Cecilia (Pinkham) Snieckus Two Children Darius Victor (b. 1967) Naomi Marie (b. 1970) Languages English, French, German, Lithuanian, Estonian Outside Interests History of Science, Jazz, Table Tennis EDUCATION Preuniversity Germany, 1945-48 Alberta, Canada, 1948-55 B.Sc. (Honors) University of Alberta, 1959 M.Sc. University of California, Berkeley, 1961 (with D.S. Noyce) Ph.D. University of Oregon, 1965 (with V. Boekelheide) Postdoctoral National Research Council, Ottawa, 1965-66 (with O.E. Edwards) ACADEMIC POSITIONS University of Waterloo Assistant Professor 1967-71 Associate Professor 1971-79 Professor 1979-92 Monsanto/NSERC Ind Res Chair 1992-98 Queen’s University Bader Chair in Organic Chemistry 1998- Bader Chair in Organic Chemistry Emeritus 2009- Brock University Adjunct Professor, Organic Chemistry 2009- Snieckus Innovations Director 2009- RESEARCH INTERESTS The Snieckus group has contributed to the development and application of the directed ortho metalation reaction (DoM) and used it as a conceptual platform for discovery of new efficient methods for the 6 HETEROCYCLES, Vol. 88, No. 1, 2014 regioselective synthesis of polysubstituted aromatics and heteroaromatics. The directed remote metalation (DreM) reaction and DoM – linked transition metal catalyzed cross coupling (especially Suzuki-Miyaura) were first uncovered in his laboratories.
    [Show full text]